Please assess the completion status of the following clinical trial:

Trial Title: Effect of Pegvisomant on GH/IGF-I Relationship in GHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years of age~* Confirmed severe AGHD~* GH response \<9 mU/l (preferably \<4) to insulin-induced hypoglycaemia or glucagon stimulation test plus (These tests will have taken place as part of routine management).~* Full, stable pituitary replacement therapy~* Willing to provide informed consent~Exclusion Criteria:~* Unwilling to provide written consent~* Current GH therapy~* Pharmacological doses of glucocorticoids~* Any acute illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).